The present invention provides methods for treating a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer comprising periodically administering to the human patient chemotherapy comprising an amount of docetaxel； and 640mg of an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, thereby treating the human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer. The present invention also provides compositions and combinations, packages, and uses thereof for treating a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer.本發明提供治療患有不可切除之晚期或轉移性非小細胞肺癌之人類患者的方法，該等方法包含向該人類患者週期性投與包含一定量多西他賽(docetaxel)的化學療法及640mg具有序列CAGCAGCAGAGTCTTCATCAT(Seq.ID No.：1)之抗叢生蛋白寡核苷酸，其中該抗叢生蛋白寡核苷酸具有貫穿整個之硫代磷酸酯主鏈，具有帶有2'-O-甲氧基乙基修飾之核苷酸1至4及18至21的糖部分，具有為2'去氧核苷酸之核苷酸5至17，且於核苷酸1、4及19處具有5-甲基胞嘧啶，藉此治療該患有不可切除之晚期或轉移性非小細胞肺癌之人類患者。本發明亦提供組合物及組合、包裝及其用途，其用於治療患有不可切除之晚期或轉移性非小細胞肺癌之人類患者。
